Equity · Healthcare
TNGX
NASDAQTango Therapeutics (TNGX)
The line runs 25 USD on 24 August through 24.91 USD on 25 September, on a scale from 20 to 26. Days the market did not trade hold the previous close, flat.
- Market cap
- 4.2B USD
- Revenue, year to Dec 2025
- 62.4M USD
- EPS, diluted, year to Dec 2025
- −0.87 USD
- 52-week range
- 6.91 USD – 32.91 USD
- Avg volume
- 257.3K
as of Sep 25, 2026
Have Tango Therapeutics (TNGX) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Tango Therapeutics insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 23 Oct 2025, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 2 Nov 2026
Buys 0Sells 5Net sold $1.73MOther filings 3
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Nov 2026 | Crystal AdamPresident, R&D | Sell | 5,000 | 112K USD |
| 02 Nov 2026 | Newcomb JessicaPrincipal Accounting Officer | Sell | 7,031 | 158K USD |
| 01 Oct 2026 | Crystal AdamPresident, R&D | Sell | 27,000 | 661K USD |
| 22 Sep 2026 | Newcomb JessicaPrincipal Accounting Officer | Sell | 8,200 | 199K USD |
| 01 Sep 2026 | Crystal AdamPresident, R&D | Sell | 27,000 | 604K USD |
| Sold | 5 open-market sales | 74,231 | $1.73M |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Nov 2026 | Crystal AdamPresident, R&D | Option exercise | 5,000 | 15K USD |
| 01 Oct 2026 | Crystal AdamPresident, R&D | Option exercise | 27,000 | 140K USD |
| 01 Sep 2026 | Crystal AdamPresident, R&D | Option exercise | 27,000 | 140K USD |
Which funds hold Tango Therapeutics (TNGX)?
1 of the 45 institutional funds we track reported a Tango Therapeutics position for the quarter ended 30 Sep 2026 — a combined 26.7M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Added | 1,068,505 | 26.7M USD | +84.8% |
What has been filed or recorded for Tango Therapeutics (TNGX)?
The filings we hold for Tango Therapeutics, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 01 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 159,538 shares | 4.0M USD notional · 0.095% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 2,937 shares | 72K USD notional · 0.002% of shares out |
| 29 Sep 2026 | Fails to deliver | Shares failed to deliver | 2,251 shares | 55K USD notional · 0.001% of shares out |
| 28 Sep 2026 | Fails to deliver | Shares failed to deliver | 1 shares | 25 USD notional · <0.001% of shares out |
| 24 Sep 2026 | Fails to deliver | Shares failed to deliver | 491,105 shares | 12.0M USD notional · 0.291% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.37 USD | |
| 30 Jun 2026 | Financials | Total assets | 1.1B USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 1.0B USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.32 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.87 USD | Revenue $62M |
| 31 Dec 2025 | Financials | Revenue | 62.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −101.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.87 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.13 USD | Revenue $54M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.35 USD | Revenue $3M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.36 USD | Revenue $5M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.19 USD | Revenue $42M |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.27 USD | Revenue $12M |
Tango Therapeutics (TNGX): frequently asked questions
What did Tango Therapeutics shares close at?
Tango Therapeutics closed at 24.91 USD on 25 Sep 2026, up 1.12% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Tango Therapeutics’ market cap?
Tango Therapeutics is worth 4.2B USD by market value as of 25 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Tango Therapeutics’ revenue?
Tango Therapeutics reported revenue of 62.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Tango Therapeutics insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Tango Therapeutics insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 23 Oct 2025, show no open-market purchase. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Tango Therapeutics?
1 of the 45 funds we track reported a Tango Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Tango Therapeutics last report earnings?
Tango Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.37 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings